The DLX5 Knockout HAP1 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population designed for functional analysis of the DLX5 gene. This heterogeneous pool of HAP1 cells carries targeted disruptions at the DLX5 locus, generating a loss-of-function model without clonal isolation. The polyclonal format preserves population-level diversity while enabling robust assessment of DLX5-dependent phenotypes. This product serves as a versatile tool for investigating the mechanisms by which DLX5 regulates osteoblast differentiation and craniofacial development.
The host cell line, HAP1, is a near-haploid human line derived from the KBM-7 chronic myeloid leukemia (CML) lineage. With a male genetic background, it carries the BCR-ABL fusion and maintains a predominantly haploid karyotype, except for disomy of chromosome 8. Its near-haploidy simplifies genetic analysis by reducing allelic complexity, while the intact CML signaling context may provide a unique milieu for studying gene function in hematopoietic cells.
DLX5 encodes a homeobox transcription factor essential for osteoblast differentiation, craniofacial development, and limb patterning. It functions downstream of BMP signaling: ligands BMP2 and BMP4 bind receptors (BMPR1A/B, BMPR2), activating SMAD1/5/8 complexes that induce DLX5 expression. DLX5 then cooperates with RUNX2 to regulate key downstream targets, including BGLAP (osteocalcin), ALPL (alkaline phosphatase), COL1A1, and SP7 (osterix). It also interacts with DLX2, MSX1, and histone acetyltransferases. Crosstalk with Wnt/??-catenin and Hedgehog pathways further modulates its activity, positioning DLX5 at a nexus of osteogenic regulatory networks.
In HAP1 cells, the single-copy genome allows clear attribution of phenotypes to DLX5 disruption, avoiding confounding effects from a second allele. Although HAP1 is of hematopoietic origin, it retains BMP-responsive signaling components and can be stimulated with recombinant BMP2/BMP4 to activate downstream pathways. This model is therefore well-suited for studying DLX5-dependent transcriptional regulation and signaling dynamics in a genetically clean system, facilitating high-content screening and mechanistic dissection without the complexity of osteogenic differentiation protocols.
Typical applications include western blotting to confirm DLX5 knockout, RT-qPCR to assess expression of downstream effectors like BGLAP and ALPL, and alkaline phosphatase activity measurements following BMP treatment. RNA-seq enables transcriptome-wide discovery of DLX5-dependent genes, while ChIP-seq maps its genomic binding patterns. These cells also support functional rescue experiments, protein interaction studies, and screening for compounds that modulate osteogenic signaling. They are valuable for research into bone density disorders, split-hand/foot malformation, and craniofacial dysplasia, as well as for drug discovery targeting BMP/Wnt axes. For further information, please contact Ascent Research.
